Cargando…

Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis

BACKGROUND: The HAS-BLED and ORBIT scores have been proposed to assess bleeding risk in anticoagulated atrial fibrillation patients. We performed a systematic review and meta-analysis to compare the predictive ability by using these two scores. MATERIALS AND METHODS: We searched the Cochrane Library...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cen, Yu, Ye, Zhu, Wengen, Yu, Jianhua, Lip, Gregory Y.H., Hong, Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752553/
https://www.ncbi.nlm.nih.gov/pubmed/29312640
http://dx.doi.org/10.18632/oncotarget.19858
_version_ 1783290130555994112
author Wang, Cen
Yu, Ye
Zhu, Wengen
Yu, Jianhua
Lip, Gregory Y.H.
Hong, Kui
author_facet Wang, Cen
Yu, Ye
Zhu, Wengen
Yu, Jianhua
Lip, Gregory Y.H.
Hong, Kui
author_sort Wang, Cen
collection PubMed
description BACKGROUND: The HAS-BLED and ORBIT scores have been proposed to assess bleeding risk in anticoagulated atrial fibrillation patients. We performed a systematic review and meta-analysis to compare the predictive ability by using these two scores. MATERIALS AND METHODS: We searched the Cochrane Library, Elsevier and PubMed databases for related studies. Statistical analysis was performed with Revman 5.3 Manager software. We chose the C-statistic to reflect the diagnostic value. RESULTS: In our seven selected studies, the pooled C- statistic of continuous variables for major bleeding was 0.65 (0.60,0.69) for ORBIT and 0.63 (0.60,0.66) for HAS-BLED. Compared with HAS-BLED, more anticoagulated AF patients (88.45% versus 32.59%) and major bleeding events (75.57% versus 25.57%) were categorized as low risk. The ORBIT score had a 1.21, 1.73 and 1.44-fold elevated risk of major bleeding in the low, intermediate and high risk strata respectively. Calibration analysis demonstrated that the ORBIT score under-predicted major bleeding in the low, intermediate, and high risk stratifications, where a odds ratio of 0.64 (0.37–1.10), 0.63 (0.38–1.05) and 0.64 (0.38–1.06), respectively. CONCLUSIONS: Compared with HAS-BLED , the ORBIT score does not perform better in predicting major bleeding events in anticoagulated atrial fibrillation patients. More anticoagulated AF patients and major bleeding events were categorized as low risk when using ORBIT.
format Online
Article
Text
id pubmed-5752553
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57525532018-01-08 Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis Wang, Cen Yu, Ye Zhu, Wengen Yu, Jianhua Lip, Gregory Y.H. Hong, Kui Oncotarget Meta-Analysis BACKGROUND: The HAS-BLED and ORBIT scores have been proposed to assess bleeding risk in anticoagulated atrial fibrillation patients. We performed a systematic review and meta-analysis to compare the predictive ability by using these two scores. MATERIALS AND METHODS: We searched the Cochrane Library, Elsevier and PubMed databases for related studies. Statistical analysis was performed with Revman 5.3 Manager software. We chose the C-statistic to reflect the diagnostic value. RESULTS: In our seven selected studies, the pooled C- statistic of continuous variables for major bleeding was 0.65 (0.60,0.69) for ORBIT and 0.63 (0.60,0.66) for HAS-BLED. Compared with HAS-BLED, more anticoagulated AF patients (88.45% versus 32.59%) and major bleeding events (75.57% versus 25.57%) were categorized as low risk. The ORBIT score had a 1.21, 1.73 and 1.44-fold elevated risk of major bleeding in the low, intermediate and high risk strata respectively. Calibration analysis demonstrated that the ORBIT score under-predicted major bleeding in the low, intermediate, and high risk stratifications, where a odds ratio of 0.64 (0.37–1.10), 0.63 (0.38–1.05) and 0.64 (0.38–1.06), respectively. CONCLUSIONS: Compared with HAS-BLED , the ORBIT score does not perform better in predicting major bleeding events in anticoagulated atrial fibrillation patients. More anticoagulated AF patients and major bleeding events were categorized as low risk when using ORBIT. Impact Journals LLC 2017-08-03 /pmc/articles/PMC5752553/ /pubmed/29312640 http://dx.doi.org/10.18632/oncotarget.19858 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Meta-Analysis
Wang, Cen
Yu, Ye
Zhu, Wengen
Yu, Jianhua
Lip, Gregory Y.H.
Hong, Kui
Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis
title Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis
title_full Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis
title_fullStr Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis
title_full_unstemmed Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis
title_short Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis
title_sort comparing the orbit and has-bled bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752553/
https://www.ncbi.nlm.nih.gov/pubmed/29312640
http://dx.doi.org/10.18632/oncotarget.19858
work_keys_str_mv AT wangcen comparingtheorbitandhasbledbleedingriskscoresinanticoagulatedatrialfibrillationpatientsasystematicreviewandmetaanalysis
AT yuye comparingtheorbitandhasbledbleedingriskscoresinanticoagulatedatrialfibrillationpatientsasystematicreviewandmetaanalysis
AT zhuwengen comparingtheorbitandhasbledbleedingriskscoresinanticoagulatedatrialfibrillationpatientsasystematicreviewandmetaanalysis
AT yujianhua comparingtheorbitandhasbledbleedingriskscoresinanticoagulatedatrialfibrillationpatientsasystematicreviewandmetaanalysis
AT lipgregoryyh comparingtheorbitandhasbledbleedingriskscoresinanticoagulatedatrialfibrillationpatientsasystematicreviewandmetaanalysis
AT hongkui comparingtheorbitandhasbledbleedingriskscoresinanticoagulatedatrialfibrillationpatientsasystematicreviewandmetaanalysis